Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.72 |
| ▸ | HPGD | P15428 | 4/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emoxypine SCHEMBL195347 | 1.00 | KDM4E (0.72) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| Emoxypine SCHEMBL1373708 | 0.98 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| Emoxypine SCHEMBL11089142 | 0.98 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| Emoxypine SCHEMBL31074958 | 0.98 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| Emoxypine SCHEMBL26983696 | 0.96 | KDM4E (0.67) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| Emoxypine SCHEMBL21061700 | 0.96 | KDM4E (0.73) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| Emoxypine SCHEMBL1373711 | 0.96 | KDM4E (0.67) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| Emoxypine SCHEMBL11089145 | 0.94 | KDM4E (0.64) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| Emoxypine SCHEMBL1010987 | 0.87 | KDM4E (0.56) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| Emoxypine SCHEMBL30182715 | 0.87 | KDM4E (0.56) | KDM4EALDH1A1HPGDHSD17B10USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220096451-A1 | POLYVALENT DERIVATIVES OF EMOXYPINE | RIESNER VERWALTUNGS GMBH (DE) | 2022-03-31 | — | — | US | claimed |
| WO-2026107393-A2 | AAV CAPSID MODIFICATIONS THAT REDUCE IMMUNOGENICITY | THE BROAD INSTITUTE, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | disclosed |
| US-12618082-B2 | Engineered muscle targeting compositions | THE BROAD INSTITUTE, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12605470-B2 | Nanodroplet with layer-by-layer assembly | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4714496-A2 | TREATMENT OF NEURONAL CEROID LIPOFUSCINOSIS | OrfoNeuro ApS (DK) | 2026-03-25 | — | — | EP | disclosed |
| US-20260077027-A1 | PEPTIDE AND NUCLEIC ACID METHODS TO MODULATE DELIVERY OF NUCLEIC ACID STRUCTURES, POLYPEPTIDES, AND THEIR CARGOES | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4709357-A2 | EXTRACELLULAR VESICLE COMPOSITIONS AND PREPARATION | Virginia Tech Intellectual Properties, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12577282-B2 | Galectin-1/ galectin-3 chimeras and multivalent proteins | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260053906-A1 | DNA ORIGAMI VACCINES | OHIO STATE INNOVATION FOUNDATION (US) | 2026-02-26 | — | — | US | disclosed |
| US-20220106580-A1 | TARGETED CHONDROITINASE ABC FUSION PROTEINS AND COMPLEXES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-04-07 | — | — | US | disclosed |
| US-20220096451-A1 | POLYVALENT DERIVATIVES OF EMOXYPINE | RIESNER VERWALTUNGS GMBH (DE) | 2022-03-31 | — | — | US | disclosed |
| US-20220096451-A1 | POLYVALENT DERIVATIVES OF EMOXYPINE | RIESNER VERWALTUNGS GMBH (DE) | 2022-03-31 | — | — | US | disclosed |
| US-20220096451-A1 | POLYVALENT DERIVATIVES OF EMOXYPINE | RIESNER VERWALTUNGS GMBH (DE) | 2022-03-31 | — | — | US | disclosed |
| US-20220098258-A1 | GALECTIN-1/ GALECTIN-3 CHIMERAS AND MULTIVALENT PROTEINS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-03-31 | — | — | US | disclosed |
| US-20220073589-A1 | GPR156 Variants And Uses Thereof | REGENERON PHARMACEUTICALS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-11266711-B2 | Oxytocin compositions and methods of use | ELGAN PHARMA LTD (IL) | 2022-03-08 | — | — | US | disclosed |
| WO-2022040612-A1 | INJECTABLE HYDROGELS AND METHODS OF CAPTURING CELLS USING THE SAME | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022018705-A1 | A PHARMACEUTICAL COMPOSITION FOR TREATING CARDIOVASCULAR AND CEREBROVASCULAR DISORDERS,DISEASES IN PREGNANT WOMEN AND IMPROVING EXERCISE TOLERANCE | M.T.K. MEDICAL CENTER LIMITED LIABILITY COMPANY (UA) | 2022-01-27 | — | — | WO | disclosed |
| WO-2022020616-A1 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | THE BROAD INSTITUTE, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618082-B2 | Engineered muscle targeting compositions | MUSK, MYO3B, MYOF | KDM4E 1369/4885ALDH1A1 4196/4885HPGD 4374/4885 |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | KDM4E 2486/4885ALDH1A1 756/4885HPGD 502/4885 |
| US-12577282-B2 | Galectin-1/ galectin-3 chimeras and multivalent proteins | LGALS1, LGALS3BP, LGALS3 | KDM4E 2556/4885ALDH1A1 4288/4885HPGD 4845/4885 |
| US-20220096451-A1 | POLYVALENT DERIVATIVES OF EMOXYPINE | PARK7, SNCA, COMT | KDM4E 2131/4885ALDH1A1 3854/4885HPGD 1856/4885 |
| US-20260053906-A1 | DNA ORIGAMI VACCINES | CD47, RBM26, TP53 | KDM4E 2778/4885ALDH1A1 4533/4885HPGD 4542/4885 |
| US-20260077027-A1 | PEPTIDE AND NUCLEIC ACID METHODS TO MODULATE DELIVERY OF NUCLEIC ACID STRUCTURES, POLYPEPTIDES, AND THEIR CARGOES | MICA, PDCD1LG2, TLR9 | KDM4E 4172/4885ALDH1A1 4810/4885HPGD 4840/4885 |
| US-12605470-B2 | Nanodroplet with layer-by-layer assembly | FLNB, FLNA, DAGLB | KDM4E 3599/4885ALDH1A1 3021/4885HPGD 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.